The 14 references in paper O. Ilyicheva E., О. Ильичева Е. (2006) “РОЛЬ МОЗГОВОГО НАТРИЙУРЕТИЧЕСКОГО ПЕПТИДА В ДИАГНОСТИКЕ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У БОЛЬНЫХ, НАХОДЯЩИХСЯ НА ПРОГРАММНОМ ГЕМОДИАЛИЗЕ // ROLE OF BRAIN NATRIURETIC PEPTIDE IN DIAGNOSING HEART FAILURE IN PATIENTS ON PROGRAM HEMODIALYSIS” / spz:neicon:nefr:y:2006:i:2:p:38-41

1
Бикбов БТ, Томилина НА. О состоянии заместитель­ ной терапии больных с хронической недостаточностью в Российской Федерации в 2000 г (Отчет по данным Россий­ ского регистра). Нефрология и диализ 2002; 4(3): 148-170
(check this in PDF content)
2
Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999; 31 (9): 487-498
(check this in PDF content)
3
Oral I, Stejskal D, Loucky J et al. Impact of acute fluid restriction on levels of natriuretic peptides in patients on a chronic dialysis program. Vnitr Lek 2004; 50 (11): 812-817
(check this in PDF content)
4
Carr SJ, Bavanandan S, Fentum B. Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci (Lond) 2005; 109 (1): 75-82
(check this in PDF content)
5
Safley DM, Awad A, Sullivan RA et al. Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. Adv Chronic Kidney Dis 2005; 12 (1): 117-124
(check this in PDF content)
6
Scbiller NB, Sbab PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two­ dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367
(check this in PDF content)
7
Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458
(check this in PDF content)
8
Abergel Е, Tase М, Bohlader J. Which definition echocardiographic left ventricular hypertrophy? Am J Cardiol 1995; 75: 489-503
(check this in PDF content)
9
Canau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558
(check this in PDF content)
10
Национальные рекомендации по диагностике и ле­ чению ХСН (утвержденные съездом кардиологов РФ в ок­ тябре 2003 г). Сердечная недостаточность 2003; 6: 276-297
(check this in PDF content)
11
Сторожаков ГИ,Томилина НА, Шило ВЮ, Гендлин ГЕ. Сердечная недостаточность у больных с хронической по­ чечной недостаточностью. Сердечная недостаточность 2005; 5(3): 100-104
(check this in PDF content)
12
Dao Q, Krishnaswamy P, Kazanegra R et al. Utility of B- type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379-385
(check this in PDF content)
13
Cowie M, Struthers A, Wood D еt al. Value of natriuretic peptides in assessment of patient with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353
(check this in PDF content)
14
Bay M, Kirk V, Parner J et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003; 89: 150-154 Поступила в редакцию 24.12.2005 г.
(check this in PDF content)